HeraMED

HeraMED Current Assets

The Current Assets of HeraMED (HMD.AX) as of Nov 2, 2026 is 3.71 M AUD. In the previous year, Current Assets was 2.02 M AUD — a change of 84.08% (higher).

Current Assets

3.71 MAUD

YoY

84.08%

Last updated:

Current Assets of HeraMED is 2024 3.71 M AUD. Current Assets of HeraMED was 2023 2.02 M AUD. It decreases by 84.08% higher compared to the previous year.

The HeraMED Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2017
121,000.00 AUD
Jan 1, 2018
4.32 M AUD
Jan 1, 2019
2.10 M AUD
Jan 1, 2020
1.97 M AUD
Jan 1, 2021
5.65 M AUD
Jan 1, 2022
4.96 M AUD
Jan 1, 2023
2.02 M AUD
Jan 1, 2024
3.71 M AUD
The HeraMED Current Assets history
YEARCurrent AssetsYoY
3.71 MAUD+84.08%
2.02 MAUD-59.34%
4.96 MAUD-12.18%
5.65 MAUD+186.30%
1.97 MAUD-6.20%
2.10 MAUD-51.26%
4.32 MAUD+3,467.27%
121,000.00AUD-91.08%
1.36 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HeraMED Stock analysis

What does HeraMED do? HeraMED Ltd. generates revenue through the sale of hardware solutions and related software applications. Its flagship product, HeraBEAT, is a medical-grade, clinically-validated connected Ultrasound Fetal Doppler device designed for expectant mothers to self-monitor their fetus' heart rate at home. The device connects via Bluetooth Low Energy to smartphones, transmitting data to a dedicated app that displays readings. The company also offers a homecare pregnancy solution service, leveraging AI and machine-learning algorithms to analyze fetal data and provide insights to healthcare professionals or home users. Sales are primarily directed to expectant mothers seeking home monitoring tools and healthcare providers integrating these solutions into patient care. HeraBEAT is marketed as a clinically-validated tool for home use, distinguishing it from standard consumer devices. The product’s integration with smartphone applications enables real-time data access, appealing to tech-savvy parents. The homecare pregnancy solution complements the hardware by offering ongoing support through AI-driven analysis, enhancing user engagement and retention. Healthcare professionals benefit from the data insights provided, potentially incorporating HeraBEAT into routine prenatal care protocols. The company’s revenue streams are built around direct sales of HeraBEAT devices and subscription-based services tied to the homecare solution. Expectant mothers purchase the hardware and access the software interface, while healthcare providers may adopt the service model for patient monitoring. AI and machine-learning capabilities are embedded in the product offering, positioning HeraMED as a provider of both medical devices and data-driven health services. HeraMED is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HeraMED stock

Current Assets of HeraMED is 3.71 M AUD in 2024.

Current Assets of HeraMED changed from 2.02 M AUD to 3.71 M AUD, representing a 84.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets HeraMED since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's HeraMED historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — HeraMED

All Key Metrics — HeraMED